PlainPharmaWatch

CMS Open Payments · Program Year 2024

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. reported $17,843,472.30 in payments to 2,488 physicians and teaching hospitals across 6,193 transactions.

See the rankings → How this is sourced
$17.8M
Total payments
6,193
Transactions
2,488
Recipients
+$153.1K
General Payments vs PY2023

Ultragenyx Pharmaceutical Inc. reported $17,843,472.30 in payments to 2,488 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #102 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $7.2K per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Ultragenyx Pharmaceutical Inc. pairs top-10% payment volume with a broadly spread payment pattern across many recipients.

#102
of 1,925 companies
0.1%
of all US industry payments
0.2%
paid to its single top recipient
7
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Ultragenyx Pharmaceutical Inc.'s CMS-reported General Payments increased by $153.1K (+50.8%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: ULTRAGENYX PHARMACEUTICAL INC.PY2023: ULTRAGENYX PHARMACEUTICAL INC.PY2024: Ultragenyx Pharmaceutical Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$301.5KPY2024$454.6K
PY2023
$301,506.20
PY2024
$454,574.21

How Ultragenyx Pharmaceutical Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Ultragenyx Pharmaceutical Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$17,843,472 Top 5% higher than 95% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Ultragenyx Pharmaceutical Inc.

$17,843,472.30: that is what Ultragenyx Pharmaceutical Inc. reported in payments to 2,488 physicians and teaching hospitals during Program Year 2024, spread across 6,193 transactions ($2.9K per transaction, $7.2K per recipient). The company sits at rank #102 of 1,925, representing 0.1% of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 7-category general-payment breakdown below at $207.1K (1.2% of the company's reported total, 58 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Consulting Fee" leads Ultragenyx Pharmaceutical Inc.'s 7-category general-payment breakdown at $207.1K, 1.2% of the reported total.

How Ultragenyx Pharmaceutical Inc. divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$207.1K2. Compensation for Services…$107.3K3. Food and Beverage$62.6K4. Travel and Lodging$38.7K5. Grant$27.0K6. Space Rental or Facility …$11.5K7. Education$330.00
Payment Type Amount Transactions
Consulting Fee $207.1K 58
Compensation for Services Other Than Consulting $107.3K 26
Food and Beverage $62.6K 2,328
Travel and Lodging $38.7K 59
Grant $27.0K 2
Space Rental or Facility Fees $11.5K 4
Education $330.00 11

Recipient Concentration in General Payments

The five largest recipient relationships account for $197,341.04 (43.4%) of $454,574.21 in this company's General Payments records across 2,061 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Ultragenyx Pharmaceutical Inc.

The five named recipients with the highest reported General Payments from this company

Nicholas Ah Mew$84.6KGerald Cox$31.9KLaura Konczal$30.8KJoseph Wolfsdorf$25.1KChildrens Hospital Corporati…$25.0K
  1. 1

    Nicholas Ah Mew

    $84,560.00 across 9 reported transactions

  2. 2

    Gerald Cox

    $31,850.00 across 7 reported transactions

  3. 3

    Laura Konczal

    $30,839.42 across 33 reported transactions

  4. 4

    Joseph Wolfsdorf

    $25,091.62 across 11 reported transactions

  5. 5

    Childrens Hospital Corporation

    $25,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $2.9K. Average per recipient: $7.2K.

Total Amount

$17,843,472.30

Avg per Transaction

$2.9K

Avg per Recipient

$7.2K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Ultragenyx Pharmaceutical Inc. Share

0.1%

#102 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Ultragenyx Pharmaceutical Inc.

Becton, Dickinson and Company

$17.8M 12,620 recipients

CSL Plasma Inc.

$17.9M 12,905 recipients

Taiho Oncology, Inc.

$17.6M 5,970 recipients

Spinecraft, LLC

$18.2M 27 recipients

Sun Pharmaceutical Industries Inc.

$18.3M 77,951 recipients

Sarepta Therapeutics, Inc.

$17.2M 1,307 recipients

Frequently Asked Questions

How much did Ultragenyx Pharmaceutical Inc. pay to physicians and hospitals in 2024? ▾
0.1% of all industry payments reported to CMS Open Payments for 2024 came from Ultragenyx Pharmaceutical Inc., totaling $17,843,472.30 across 6,193 transactions to physicians and hospitals.
How many physicians received payments from Ultragenyx Pharmaceutical Inc.? ▾
Averaging $7.2K per recipient, Ultragenyx Pharmaceutical Inc.'s 2024 payments reached 2,488 physicians and teaching hospitals.
What types of payments did Ultragenyx Pharmaceutical Inc. make? ▾
General payments from Ultragenyx Pharmaceutical Inc. span 7 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Consulting Fee" at $207.1K, representing 1.2% of the company's reported total.
How does Ultragenyx Pharmaceutical Inc. rank among pharmaceutical companies? ▾
By total payment amount, Ultragenyx Pharmaceutical Inc. sits at #102 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Ultragenyx Pharmaceutical Inc.? ▾
The average transaction from Ultragenyx Pharmaceutical Inc. was $2.9K in 2024. The company made 6,193 total transactions to 2,488 recipients.
Where does the payment data for Ultragenyx Pharmaceutical Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Ultragenyx Pharmaceutical Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.